Nautilus Neurosciences, Inc. Announces the Sale of CAMBIA® (Diclofenac Potassium for Oral Solution) to Depomed, Inc. for Total Consideration of Up to $53.7 Million Business Wire BEDMINSTER, N.J. -- December 17, 2013 Nautilus Neurosciences, Inc. has completed a transaction for the sale of the U.S. and Canadian rights to CAMBIA® (diclofenac potassium for oral solution) to Depomed, Inc. (NASDAQ: DEPO). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of migraine attacks with or without aura in adults ages 18 years of age or older. Under the terms of the agreement, Depomed will acquire the rights to CAMBIA in return for total consideration of up to $53.7 million in cash of which $48.7 million is upfront and $5.0 million is payable upon reaching certain milestones based on future annual net sales. Cambia is licensed to Tribute Pharmaceuticals in Canada. “We congratulate Depomed on the acquisition of Cambia. Cambia has provided relief to thousands of migraine sufferers in the United States since Nautilus launched the product in 2010,”said William Maichle, Chief Executive Officer of Nautilus Neurosciences. “We are confident that Depomed will continue to provide the same outstanding customer service to Healthcare Providers and patients that the Nautilus Neurosciences team has provided and wish them luck in the promotion of Cambia.” Stifel acted as the exclusive financial advisor to Nautilus Neurosciences in this transaction. About Cambia CAMBIA is a powdered formulation of diclofenac potassium that is dissolved in liquid. It has a rapid onset and has demonstrated in clinical studies relief of the pain and associated symptoms of migraine, including nausea, sensitivity to light and sensitivity to sound. It was launched in 2010. Important Safety Information CAMBIA is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may increase your chance of a heart attack or stroke that can lead to death. This chance is higher with longer use of NSAID medicines and in people who have heart disease. CAMBIA should never be used right before or after certain heart surgeries. NSAID medicines can also cause stomach and intestine problems, such as ulcers and bleeding, which can happen without warning and may cause death. This risk increases with use of steroids (corticosteroids), blood thinners (anticoagulants), smoking, alcohol use, older age, and for those in poor health. About Nautilus Neurosciences Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with medically relevant products and services that directly benefit those affected by neurologic disorders. About Depomed Depomed, Inc. is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and other products and product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com. Contact: Nautilus Neurosciences, Inc. William Maichle, 908-393-7800 email@example.com
Nautilus Neurosciences, Inc. Announces the Sale of CAMBIA® (Diclofenac Potassium for Oral Solution) to Depomed, Inc. for Total
Press spacebar to pause and continue. Press esc to stop.